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Abstract
Introduction: There have been few studies on lymphangiogenesis in the past due to the lack of
specific lymphatic endothelial markers, and lymphatic-specific growth factors. Recently, these
limitations have been relieved by the discovery of a small number of potential lymphatic-specific
markers. The relationship between lymphangiogenesis and regional or distant metastasis has not
previously been investigated in humans. Using these lymphatic markers, it is possible to explore the
relationship between lymphangiogenesis and tumour metastasis. This study indirectly quantified
lymphangiogenesis by measuring mRNA expression of all seven lymphatic markers described above
in breast cancers and correlated these markers with lymphatic involvement and survival.
The cDNA from 153 frozen archived breast samples were analysed with Q-PCR for all seven
lymphangiogenic markers. This was correlated with various prognostic factors as well as patient
survival.
Results: There was significantly greater expression of all 7 markers in malignant compared to
benign breast tissue. In addition, there was greater expression in lymph node positive/grade 3
tumours when compared to lymph node negative/grade 1 tumours. In 5 of the markers, there was
a greater expression in poor NPI prognostic tumours when compared to favourable prognostic
tumours which was not statistically significant. There was no association between recurrence risk
and lymphangiogenic marker expression.
Conclusion: In summary, the findings from this study show that lymphangiogenesis, measured by
specific lymphatic marker expression, is higher in breast cancers than in normal breast tissue.
Secondly, breast cancers which have metastasised to the regional lymphatics show higher
expression compared to those which have not, although the individual differences for all five
markers were not statistically significant.
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Introduction
Breast cancer is one of the leading causes of cancer death
in the female population in the Western World affecting
as many as one in ten women in the UK [1], and its inci-
dence appears to be rising. Although earlier diagnosis and
better treatment are now available, many of the mecha-
nisms underlying its ability to metastasise are poorly
understood. Breast cancer spreads primarily via the lym-
phatic system. Regional lymph nodes are usually the first
metastatic sites to be involved, often followed by distant
metastasis to the lungs, liver and bones. Although various
prognostic factors are known, regional lymph node status
is the single most important prognostic factor in breast
cancer; patients with axillary metastasis at the time of
diagnosis have a much worse prognosis than those with-
out metastasis [2,3].
Clinical and pathological observations have long sug-
gested that for many other tumours, the most common
pathway of initial dissemination is also via lymphatics,
with patterns of spread via afferent vessels following
routes of natural lymphatic drainage. However, the lym-
phatic system has traditionally been overshadowed by the
greater emphasis placed on angiogenesis, the formation of
new blood vessels. Indeed, it is widely accepted that ang-
iogenesis is necessary for the growth and metastatic spread
of solid tumours [4,5]. There have been relatively few
studies on lymphangiogenesis in the past due to the lack
of suitable markers that distinguish lymphatic from blood
vascular endothelium, and the lack of lymphatic-specific
growth factors. Furthermore, it is not known whether pre-
existing lymphatic vessels are sufficient to permit initial
tumour metastasis, or whether tumour dissemination
requires the development of new lymphatics [4].
In recent years, these limitations have been relieved by the
discovery of a small number of potential lymphatic-spe-
cific markers [5]. These include: LYVE-1, a lymphatic
endothelial receptor for hyaluronan [6], Prox1, a home-
obox gene product involved in regulating early lymphatic
development [7], podoplanin, a glomerular podocyte
membrane mucoprotein which is also found on lym-
phatic endothelium, but not in blood vessels [8], 5'-nucle-
otidase, an enzyme whose activity is very high in the
lymphatic capillaries, but much lower in the blood capil-
laries [9], and the vascular endothelial growth receptor-3
(VEGFR-3) which is a transmembrane tyrosine kinase
receptor predominantly expressed on the lymphatic
endothelium [10]. VEGFR-3 has been shown to control
the development and growth of the lymphatic system [11]
VEGF-C [12] and VEGF-D [13] are two polypeptide
growth factors which are agonists of the VEGFR-3 recep-
tor, and may therefore be considered to be lymphang-
iogenic [14] These factors have been shown to be
associated with lymphatic and distant metastasis and
shorter overall survival [15]. In contrast, the angiogenic
growth factor, VEGF, does not bind to VEGFR-3.
Breast cancer angiogenesis has been clearly linked to
tumour metastasis. Using histopathological staining
methods for blood vessel endothelial markers, a signifi-
cant direct correlation was found between the highest
microvessel density in histological sections of human
invasive breast cancer and the occurrence of metastases
[16]. Notwithstanding these findings, no studies have
shown that angiogenesis is correlated with regional lymph
node metastasis in breast cancer. The relationship
between lymphangiogenesis and regional or distant
metastasis has not previously been investigated in
humans. Real-time quantitative polymerase chain reac-
tion (QPCR) has now become an established method of
quantifying genetic sequences [17]. Using QPCR, a novel
approach for quantifying lymphatic markers has been
recently described in breast cancer, using LYVE-1 [18].
Using these new lymphatic markers, it is possible to
explore the relationship between lymphangiogenesis and
tumour metastasis. The aim of this study was to indirectly
quantify lymphangiogenesis by measuring mRNA expres-
sion of all seven lymphatic markers described above in
breast cancers and correlate these markers with lymphatic
involvement and survival.
Methods
Specimens
153 frozen archived breast samples from 105 patients
were kept at -80°C. The samples consisted of breast can-
cers and background benign breast tissue. Histopatholog-
ical information and patient follow-up details of the
specimens were collected but blinded until the end of the
study. 7 µm sections were cut from each specimen for his-
topathology (see below) and ten adjacent 10 µm sections
were stored for subsequent RNA extraction. Human
umbilical vein endothelial cells (HUVECs), a fibroblast
cell line (MRC-5), and two breast cancer cell lines (MB
MDA 231 and MCF7), were also cultured.
Histopathology
All samples were stained with haematoxylin and eosin for
routine histopathological assessment by a consultant
pathologist to confirm whether or not tumour was present
in the sample. The percentage of tumour, with respect to
surrounding stroma, was also estimated. Each assessment
was later compared with the patients' original histopatho-
logical reports. In addition, sections were also stained
with factor 8 monoclonal antibodies, using standard
immunohistochemical techniques. Five microscope fields
were counted for each case and summated to give a single
figure. Ten sections were blindly counted a second time to
exclude the presence of intra-observer error.Molecular Cancer 2008, 7:23 http://www.molecular-cancer.com/content/7/1/23
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RNA Extraction and cDNA Synthesis
RNA was extracted from the homogenised breast samples
and cell lines using the standard RNAzol procedure. The
concentration of RNA was measured with a UV spectro-
photometer. Equal amounts of cDNA were subsequently
synthesised from 1 µg of total RNA using a reverse tran-
scription kit (Abgene, Surrey, UK) according to the manu-
facturer's instructions.
PCR
A pair of primers specific for part of the following mole-
cules were designed, using the Beacon Designer software
(Palo Alto, California), which were based on cDNA
sequences obtained from the Gene Bank: LYVE-1, Prox1,
podoplanin, 5'-nucleotidase, VEGF-C, VEGF-D, VEGFR-3,
VEGFR-2 and β-actin. The forward and reverse primer
sequences are shown in Table 1.
Conventional PCR was also performed using cDNA of
HUVECs, MRC-5, MDA-MB-231 and MCF7 using all nine
pairs of primers. Electrophoresis of the PCR products was
performed on a 0.8% agarose gel and stained with ethid-
ium bromide prior to examination under UV light. Quan-
titation of mRNA was performed by normalisation vs CK-
19.
Plasmid Synthesis
The appropriate PCR products were TA cloned using the
PCR®2.1-TOPO vector and amplified using One-Shot E.
coli (Invitrogen, Groningen, Netherlands) following the
manufacturer's instructions. X-gal in LB agar plates was
used to identify the positive colonies. The positive colo-
nies were further verified by PCR, using the same corre-
sponding pairs of primers. The plasmids were then
extracted from the E. coli by using the plasmid mini puri-
fication kit (Qiagen, Crawley, UK) according to the man-
ufacturer's guidelines. The plasmids were digested using
the Hind III and Xba I restriction endonucleases to con-
firm the presence of the inserts. In addition the plasmids
were sequenced to confirm that they contained the correct
DNA sequences (BigDye, PE Applied Biosystems, War-
rington, UK). The concentration of each plasmid was cal-
culated and serial logarithmic dilutions were prepared.
Real-time quantitative polymerase chain reaction (QPCR)
The detection of LYVE-1 expression used a Scorpions sys-
tem. The Scorpions probe/primer was formed by linking a
forward primer and fluorescent probe using a PCR stopper
(Oswel, Southampton, UK) [19]. Taqman primers and
probes were designed for VEGFR-3 and VEGFR-2. For the
other five markers, Prox1, podoplanin, 5'-nucleotidase,
VEGF-C and VEGF-D, the Amplifluor system [20] was
used required the use of pairs of specific primers for each
marker (a forward primer and reverse Z primer), with a
universal probe (UniPrimer™) which was used for all five
markers. Using the iCycler IQ system (BioRad, Camber-
ley, UK), which incorporates a gradient thermocycler and
a 96 channel optical unit, the plasmid standards and
breast cancer cDNA were simultaneously assayed.
RTQPCR conditions were as follows: Scorpions: Denatur-
ing: 95°C for 15s; Annealing: 54°C for 20s; Extension:
60°C for 40s. Taqman: 95°C for 15s, 54°C for 20s, 60°C
for 40s. Amplifluor: 95°C for 15s, 55°C for 60s, 72°C for
20s. Using the purified plasmids as internal standards, the
level cDNA (copies/µl) of each of the seven markers in the
breast samples were calculated. Negative template con-
trols were included in during all RTQPCR procedures. The
size of the products of RTQPCR were subsequently veri-
fied on agarose gels. Primer sequences are shown in Table
2.
Statistical Analysis
After unblinding the results, mean levels of each marker
were compared in lymph node positive patients with
lymph node negative patients and background normal
breast tissue. Marker levels were also compared between
patients with good, moderate or poor prognosis tumours,
using the Nottingham Prognostic Index (NPI), and
between patients who were disease-free on follow-up and
those with recurrence or who had died. Statistical signifi-
cance was calculated using the Mann-Whitney U-test.
Results
Breast specimen histology and patient details
153 breast samples were analysed. Histopathological
examination confirmed that there were 120 breast cancers
and 33 normal background breast tissue samples. The per-
centage of tumour in each sample varied from 2.5% to
Table 1: Primers used for PCR analysis
Molecule PCR Primer
LYVE:1 5'-gtgcttcagcctggtgttg-3'
5'-gcttggactcttggactcttc-3'
Prox-1 5'-atgtcatctcaccacctgag-3'
5'-gcagatgaccttgtatatgg-3'
Podoplanin 5'-tggtggaatcatcgttgtggttatgc-3'
5'-acaagtgaacctcctgcctcctc-3'
5'-Nucleotidase 5'-tggagtgatcggttacagaatgc-3'
5'-gctggtgccgctgtgagtc-3'
VEGF-C 5'-ggcttctcctggtgacatctg-3'
5'-ttgcttgggacacattgacattc-3'
VEGF-D 5'-ctaatgtcaactgcttag-3'
5'-atggtctggtatgaaagg-3'
VEGFR-3 5'-gcgactgtggctctg-3'
5'-gaaaggaagtcctggtctc-3'
VEGFR-2 5'-gcctctgtgggtttgcctagtgtttc-3'
5'-gctgatcatgtagctgggaat-3'
β-actin 5'-atgatatcgccgcgctcgt-3'
5'-cgctcggtgaggatcttca-3'
Please note for all tables, the number in parentheses gives the number 
of samples valid for analysis following PCR.Molecular Cancer 2008, 7:23 http://www.molecular-cancer.com/content/7/1/23
Page 4 of 10
(page number not for citation purposes)
100% (mean 48.0; sd 27.8). Using factor 8 immunohisto-
chemical staining, the mean vessel counts for the breast
cancers and normal breast tissue were 45.7 ± 23.2 and
51.7 ± 21.0, respectively (t-test: P = 0.116).
Expression of lymphatic markers in cell lines and tissues
A comparison was made of the expression of β-actin and
the eight markers in the following cell lines: HUVECs,
MRC-5, MDA-MB-231 and MCF7. LYVE-1, Prox1, podo-
planin, 5'-nucleotidase, VEGFR-2 and VEGFR-3 were
expressed in HUVECs. In addition, Prox1 and 5'-nucleoti-
dase were expressed in MDA-MB-231 cells and VEGFR-2
was weakly expressed in MRC-5 cells. In contrast, VEGF-C
and VEGF-D were not expressed in HUVECs, but were
both expressed in the aggressive breast cancer cell line,
MDA-MB-231. In addition, VEGF-C was expressed in
MRC-5 fibroblast cells and VEGF-D was expressed in the
MCF7 breast cancer cell line.
Quantitation of markers in normal breast tissue and breast 
cancer
153 breast samples were analysed. Gel electrophoresis of
all QPCR products of the different markers confirmed that
the products were of the correct size. It was found that the
mean expression levels for breast cancer were statistically
significantly higher than normal breast tissue for all seven
lymphatic markers (Table 3). There was no significant dif-
ference in VEGFR-2 expression between the two groups.
Quantitation of markers in lymph node positive and 
negative breast cancer
It was found that mean expression levels were higher in
tumours which had metastasised to the axillary lymph
nodes (node positive) than in tumours which had not
metastasised (node negative) for all five lymphatic
endothelial markers and the two growth factors (Table 4).
However, individually, none of these differences reached
statistical significance. Expression of VEGFR-2 was higher
in node negative tumours, but this difference was not sig-
Table 2: Primers used for Q-PCR analysis
Molecule Q-PCR Primer
LYVE-1 5'-FAM-CCGCGGGATGGAAAGCTCTTCTGCCGCGG-MR-HEG-GGTCCAAGGCTCTTTGCGT-3'
5'-AAATTCAGCTGCTGGTTCGC-3'
VEGFR-3 5'-ACGGCCTGGTGAGTGGC-3'(Forward)
5'-CGTTTGACTCCTCCGTGATG-3' (Reverse)
5'-FAM-CCATGACCCCCC CGACCTTGA-3' [53]
VEGFR-2 5'-TGTGGCTCTGCGTGGAGA-3' (Forward)
5'-GGGCAGATCAAGAGAAACACTAGG-3' (Reverse)
5'-FAM-CGGGCCGCCTCTGCGGGTTT-3' [54]
Prox-1 5'-GCAGGAAAAGTTCTACCA-3' (Forward)
Z: 5'-TCTTCAGACAGGTTACCATC-3' (Reverse)
Podoplanin 5'-GAATCATCGTTGTGGTTATG-3' (Forward)
Z: 5'-CTTTCATTTGCCTATCACAT-3' (Reverse)
5'nucleotidase 5'-tcgacctcctggagtgatcgg-3' (Forward)
Z: 5'-cacccgatgataggcttctc-3' (Reverse)
VEGF-C Z: 5'-GCTTCTCCTGGTGACATC-3' (Forward)
5'-CCTGAGTCCCTCGTCTCT-3' (Reverse)
VEGF-D 5'-GCTCCAGTAATGAACATGG-3' (Forward)
Z: 5'-ATCTGCTGTTCAGATCGTT-3' (Reverse)
Please note for all tables, the number in parentheses gives the number of samples valid for analysis following PCR.
Table 3: Levels of mRNA transcript in tumour vs normal tissue
TUMOUR NORMAL BREAST P-VALUE
LYVE-1 57.0 ± 326.3 01 (93) 0.28 ± 0.37 (23) < 0.0001
Prox1 5099.1 ± 8353.1 (119) 1270.2 ± 1555.4 (32) 0.0009
Podoplanin 13722 ± 67277 (120) 4973 ± 7115 (29) 0.0483
5'-Nucleotidase 4964.4 ± 7166.3 (112) 3208.1 ± 8760.9 (32) 0.0068
VEGFR-3 121.76 ± 223.84 (120) 65.64 ± 197.00 (32) 0.0104
VEGF-C 1899.2 ± 8596.4 (84) 270.4 ± 305.5 (23) 0.0255
VEGF-D 57.3 ± 113.1 (58) 11.7 ± 12.2 (15) 0.0163
VEGFR-2 5.87 ± 16.17 (116) 4.01 ± 12.39 (31) 0.9017
VEGF-C:VEGF-D ratio 137.4 ± 60.1 160 ± 111 0.3694
Please note for all tables, the number in parentheses gives the number of samples valid for analysis following PCR.Molecular Cancer 2008, 7:23 http://www.molecular-cancer.com/content/7/1/23
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nificant. It has recently reported that the VEGF-C:VEGF-D
ratio may be a better prognostic marker [21,22]. Here we
also examined the VEGF-C/VEGF-D ratio, which proved
to be a better marker in distinguishing node negative from
node positive tumours (ratio being 317 ± 167 for node
positive and 45 ± 19 for node negative tumours, p =
0.0369, Table 5).
Correlations with tumour size, ER status, grade and type, 
NPI and survival
Although most of the differences for each marker failed to
reach statistical significance, the trend was for grade three
tumours to have the highest marker expression and grade
one tumours to have the lowest expression (Table 6).
Marker expression was compared between the two com-
monest tumour types, ductal and lobular adenocarci-
noma (Table 7) with no consistent pattern of expression
observed. In five out of the six lymphatic markers, expres-
sion was found to be highest in the poor NPI prognosis
group, although most of the differences were not statisti-
cally significant (Table 8). Neither tumour size nor ER
positivity (Table 9) was correlated with marker expres-
sion. Finally, after comparing expression levels between
tumours in which the patients were alive and well on clin-
ical follow-up and those who had had recurrence of their
breast cancer (Table 7), we did not find any consistent pat-
tern between the groups after a median follow-up of 72
months. None of the comparisons were significant
(Mann-Whitney > 0.05 for all markers).
Discussion
This is the first attempt to quantify lymphangiogenesis in
tissues from a cohort of cancer patients. Moreover, we
have assayed all currently known lymphatic markers, as
well as an angiogenic marker. It was found that all lym-
phatic endothelial markers, LYVE-1, Prox1, podoplanin,
5'-nucleotidase and VEGFR-3, were expressed in signifi-
cantly higher levels in breast cancers than in normal breast
tissue. Since this indirectly reflects the rate of synthesis of
lymphatics, this confirms for the first time that lymphang-
iogenesis is greater in breast cancer than it is in normal
breast tissue. This contrasts with the historical view that
tumours do not contain any functional lymphatic system
[21]. Secondly, lymphangiogenesis appears greater in
tumours which have metastasised to the regional lymph
nodes than in tumours which have not metastasised.
Although the differences between node positive and neg-
ative tumours were not statistically significant for individ-
ual markers, all five markers expressed higher levels in the
node positive breast cancers. In addition, the VEGF-
Table 4: Level of mRNA transcript in node +ve vs node -ve tumours
Node +ve Node -vE P-Value
LYVE-1 128.0 ± 231.9 (36) 12.1 ± 18.2 (57) 0.89
Prox-1 6140.0 ± 10922.0 10571 4466.0 ± 6309.0 (74) 0.82
Podoplanin 23306.0 ± 105711.0 (46) 7764.0 ± 19895.0 (74) 0.125
5'Nucleotidase 5170.4 ± 6676.5 (42) 4840.8 ± 7489.2 (70) 0.550
VEGFR-3 129.4 ± 238.3 (46) 117.0 ± 215.9 (74) 0.480
VEGF-C 3989.0 ± 13759.0(32) 613.1 ± 877.4 (52) 0.622
VEGF-D 114.5 ± 186.7 1 31.5 ± 36.1 (40) 0.286
VEGFR-2 4.2 ± 14.8 (43) 6.8 ± 17.0 (73) 0.570
VEGF-C:VEGF-D ratio 317.0 ± 167.0 45.0 ± 19.0 0.0369
Please note for all tables, the number in parentheses gives the number of samples valid for analysis following PCR.
Table 5: Levels of mRNA transcript vs tumour grade
Grade 1 Grade 2 Grade 3
LYVE-1 12.3 ± 30.2 (20) 67.0 ± 328.4 (33) 70.9 ± 401.2 (40)
Prox1 7083 ± 9542 (24) 2727 ± 4693 (41) 5536 ± 9999 (55)
Podoplanin 3099 ± 3579 (24) 12774 ± 26291 (41) 18775 ± 95973 (56)
5'-Nucleotidase 5187 ± 7647 (22) 4652 ± 7725 (38) 5615 ± 10888 (52)
VEGFR-3 110 ± 161 (24) 122 ± 206 (41) 127 ± 259 (56)
VEGF-C 702 ± 270 (15) 1664 ± 942 (29) 2290 ± 1768 (42)
VEGF-D 44.3 ± 17.1 (14) 26.2 ± 6.23 (17) 62.6 ± 26.3 (29)
VEGFR-2 15.9 ± 30.5 (24) 5.1 ± 11.2 (39) 1.8 ± 3.4 (54)
VEGF-C/VEGF-D ratioR-2 160 ± 130 236 ± 176 65.9 ± 26.5
Please note for all tables, the number in parentheses gives the number of samples valid for analysis following PCR.Molecular Cancer 2008, 7:23 http://www.molecular-cancer.com/content/7/1/23
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C:VEGF-D ratio ratio however was significantly higher in
the node node +ve group which concurs with previous
studies [21,22] which link this relationship to poor prog-
nosis. This suggests that a real difference may exist,
although larger sample numbers are required to confirm
this. Recent studies showing significantly increased lym-
phangiogenesis in and around metastatic lymph nodes
have supported this hypothesis [22] which may be present
before metastasis actually occurs [23,24] and may be
related to VEGF-C expressing tumour associated macro-
phages [25]
Factor 8 R:Ag has proven to be one of the best available
immunohistochemical markers for the identification of
endothelial cells [26]. Factor 8 immunohistochemistry is
a well-established method of identifying the vessel density
in histological specimens. We did not demonstrate any
significant difference in the level of factor 8 staining
between normal breast tissue and breast cancer tissue.
This suggests that the vasculature of the normal breast is
similar in density to breast cancer which supports the
observation that VEGFR-2 expression was not signifi-
cantly different between breast tumours and normal
breast tissue. It is interesting however, that other groups
have found a high microvessel density, measured by factor
8 immunohistochemistry, was associated with a high inci-
dence of metastasis (axillary or distant or both) in breast
cancer [27] and also that regional lymph node lymph ves-
sel density was positively correlated with lymph node
metastasis, VEGF-C expression and a poor prognosis
[28,29]
VEGF-C and VEGF-D are predominantly expressed in
human adult tissues, including heart, muscle, ovary and
small intestine, but they have also been identified in sev-
eral types of malignant tumours [30]. It is known that
VEGF-C is synthesised as a prepropeptide which under-
goes proteolytic maturation to a varying degree [31].
These shorter peptides bind to VEGFR-3, but only the fully
processed form can bind to VEGFR-2. Overexpression of
VEGF-C in the skin or pancreas of transgenic mice resulted
in lymphatic endothelial proliferation and vessel enlarge-
ment, while the blood vessels remained unaffected [32].
Furthermore, others have shown that there is a strong
association between VEGF-C expression and microlym-
phatic vessel density in human malignant mesotheliomas
[33]. In view of these findings, it is thought that VEGF-C
is predominantly a regulator of lymphangiogenesis,
although it also does promote angiogenesis to a lesser
degree. Since VEGF-D possesses a similar structure with a
comparable expression pattern, it is also thought that this
growth factor behaves similarly. In addition to promoting
lymphangiogenesis, it has now been shown that VEGF-D
promotes lymphatic metastasis in a mice [34]. Likewise,
Table 6: Levels of mRNA transcript vs tumour type
Ductal Tumours Lobular tumours P value
LYVE-1 42.4 ± 295.4 (74) 241.1 ± 666.3 (8) n/s
PROX-1 5743.0 ± 9206.0 (97) 2928.0 ± 4117 (10) n/s
PODOPLANIN 15498.0 ± 74049.0 (98) 1783.0 ± 2657.0 (10) n/s
5'-nucleotidase 4813.0 ± 6873.0 (91) 1522 ± 2371 (10) n/s
VEGFR-3 126.3 ± 239.4 (98) 99.0 ± 149.3 (10) n/s
VEGF-C 2098 ± 1093 (72) 524 ± 334 (3) n/s
VEGF-D 47.3 ± 15.8 (49) 78.6 ± 45.1 (5) n/s
VEGFR-2 4.2 ± 14.7 (94) 10.1 ± 14.5 (10) n/s
VEGF-C/VEEGF-D ratio 119.0 ± 65.5 293.0 ± 258.0 n/s
Please note for all tables, the number in parentheses gives the number of samples valid for analysis following PCR.
Table 7: Levels of mRNA transcript vs prognosis
GOOD MODERATE POOR
LYVE-1 13.8 ± 34.3 (35) 3.4 ± 6.6 (37) 272.9 ± 140.9 (17)
PROX-1 4785.0 ± 7723.0 (44) 4354.0 ± 4530.0 (49) 7638.0 ± 14562.0 (22)
PODOPLANIN 4341.0 ± 4919 (44) 10353.0 ± 22574 (49) 37811.0 ± 149439 (23)
5'-Nucleotidase 4708.0 ± 8053 (40) 44217.0 ± 4337 (45) 6471.0 ± 15237.0 (22)
VEGFR-3 117.0 ± 171.0 (44) 122.0 ± 252 (49) 133.0 ± 268.0 (23)
VEGF-C 467.0 ± 665.0 (45) 911.0 ± 1187.0 389.0( 3989.0 ± 13759.0 (32)
VEGF-D 29.3 ± 28.8 (36) 117.3 ± 198.9 (15) 83.7 ± 106.6 (6)
VEGFR-2 12.2 ± 25.0 (43) 2.1 ± 4.0 (48) 2.4 ± 4.3 (21)
VEGF-C:VEGF-D 45.0 ± 19.0 412.0 ± 77.0 (73) 77.0 ± 73.0
Please note for all tables, the number in parentheses gives the number of samples valid for analysis following PCR.Molecular Cancer 2008, 7:23 http://www.molecular-cancer.com/content/7/1/23
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using human breast cancers transplanted onto mice,
VEGF-C has also been shown to potently increase lym-
phangiogenesis and promote metastasis to regional
lymph nodes [35,36]. We have now shown in this study
that expression of VEGF-C and VEGF-D is higher in lymph
node positive than negative tumours, although the differ-
ences were not statistically significant.
LYVE-1 was first described in 1999, and is an important
hyaluronan receptor which is found on the lymph vessel
wall and related to the CD44 receptor, although its precise
function is unclear. It is completely absent from blood
vessels and, therefore, specific for lymphatics. Recent
mouse studies have used LYVE-1 in this context. The
homeobox gene Prox1 was first described in 1993. Analy-
sis of the expression pattern suggested that it has a func-
tional role in a variety of tissues, including lens, heart,
liver, pancreas and central nervous system. It has now also
been shown that Prox1 is expressed in a subpopulation of
endothelial cells that gives rise to the lymphatic system in
mice and is thought to be a specific and required regulator
for the development of the murine lymphatic system [37].
It is also absent from blood vessels, making it a useful
lymphatic marker. Since the discovery of podoplanin in
1997 [38], expression of this protein has been found in
the endothelium of lymphatic capillaries, but not in the
blood vasculature. In purely lymphatic tumours (lym-
phangiomas and hygromas), high levels of podoplanin
staining were found, whereas in purely vascular tumours,
much lower levels of staining were found when compared
to other known vascular endothelial markers. Antibodies
to podoplanin have recently been used to demonstrate
that high lymphatic microvessel density is associated with
lymph node metastasis in human breast cancer [39].
VEGFR-3 is predominantly expressed on lymphatic
endothelium, but although previous studies have used
this receptor as a specific marker for lymphatic vessels, it
has now been shown to be expressed in tumour blood
vessels during neovascularisation [40] and so cannot be
considered entirely specific for lymphatics. 5'-nucleoti-
dase is an enzyme found throughout the body, however,
its activity is significantly higher in lymphatics than blood
vessels [41]. For this reason, enzyme histochemistry has
been used in the past in order to identify lymphatics by
the light and scanning electron microscopes. The expres-
sion of this enzyme has not previously been investigated
in humans.
In this study therefore, it has been shown that expression
of those factors which have been shown to play an active
role in lymphangiogenesis is increased in malignant
human breast tissue versus its benign counterpart. This is
true both for the lymphangiogenic agonists (VEGF-D/C)
and their receptors (VEGFR-2/3) but also for the inde-
pendent markers of lymphatic activity (LYVE-1, Prox-1,
podoplanin and 5' nucleotidase). It has also been shown
that the VEGF-C:D ratio may have important prognostic
significance of it's own.
In this study, we found that all known endothelial mark-
ers, LYVE-1, Prox1, podoplanin, 5'-nucleotidase, VEGFR-3
and VEGFR-2 were expressed by the HUVECs. To date,
there are no reports describing isolation of endothelial
cells from lymphatic capillaries. HUVECs were used
because these cells are foetally-derived are therefore likely
to be at an early stage of development and differentiation.
Table 8: Levels of mRNA transcription vs outcome
ALIVE AND WELL RECURRENCE p-VALUE
LYVE-1 79.1 ± 389.0 (65) 6.1 ± 11.0 (23) 0.932
PROX-1 4568.0 ± 6729.0 (84) 7420.0 ± 12336 (31) 0.076
Podoplanin 13605.0 ± 78024 6550 9336.0 ± 15008.0 (31) 0.186
5'Nuceotidase 4230.0 ± 6550.0 (78) 8091.0 ± 14398.0 (29) 0.203
VEGFR-3 113.0 ± 229.0 (85) 149.0 ± 227.0 (31) 0.064
VEFG-C 1124.0 ± 464.0 (60) 3919.0 ± 3370.0 (22) 0.660
VEGF-D 47.9 ± 17.1(44) 60.3 ± 24.5 (12) 0.881
VEGFR-2 5.5 ± 15.2 (83) 4.1 ± 99.0 (29) 0.375
VEGFC:VEGF-D ratio 148.0 ± 78.0 108.0 ± 106.0 0.77
Please note for all tables, the number in parentheses gives the number of samples valid for analysis following PCR.
Table 9: Levels of mRNA transcripts ve Oestrogen receptor (ER) 
status
ER(-) ER(+) P value
LYVE1 53.6 ± 10.1 66.7 ± 17.9 0.53
PROX1 6394 ± 880 2860 ± 2429 0.57
Podoplanin 16923 ± 11842 5664 ± 1255 0.24
5-Nucleotidase 4358 ± 716 7544 ± 2458 0.22
VEGF-R3 111 ± 27 144 ± 39 0.47
VEGF-C 1189 ± 507 3748 ± 3222 0.44
VEGF-D 50 ± 19 33.5 ± 18 0.53
VEGF-R2 5.2 ± 1.9 6.0 ± 1.8 0.76
VEGF-C/VEGF-D ratio 128.6 ± 81.8 93.524136.6 0.70
Please note for all tables, the number in parentheses gives the number 
of samples valid for analysis following PCR.Molecular Cancer 2008, 7:23 http://www.molecular-cancer.com/content/7/1/23
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It would be expected, therefore, that these cells will
express both angiogenic and lymphangiogenic markers.
Furthermore, HUVECs have been previously shown to
express lymphatic markers, such as LYVE-1, in other stud-
ies [42]. Both VEGF-C and VEGF-D were expressed in the
breast cancer cell lines. The expression of Prox1 and 5'-
nucleotidase by MDA-MB-231 cells is interesting, possibly
explained by the poor differentiation of these cancer cells.
However, it suggests that Prox1 is less specific than origi-
nally thought.
The Nottingham Prognostic Index (NPI) for primary
breast cancer was first described in 1982 [43]. It comprises
a scoring system based on three variables of the primary
tumour, namely tumour size, grade and lymph node sta-
tus. Using this system, scores are classified into three prog-
nostic groups – good, moderate and poor. The 15-year
survivals of these groups are 80%, 42% and 13%, respec-
tively [44]. In this study we did not find any statistical evi-
dence of a correlation between a tumour prognosis and
the expression of lymphatic markers.
After following-up the breast cancer patients after a
median interval of 72 months, we did not find any differ-
ence in any marker expression levels between patients
who were still in remission from their original cancer and
patients who had had recurrence, either local or distant.
We believe the interval of 6 years to be insufficient to
show whether any difference does exist or not, since the
number of statistical events was very low.
No correlation was found between lymphatic marker
expression and either tumour grade or histopathological
type. High grade tumours carry a worse prognosis than
low grade tumours. Since this study indicates that lym-
phangiogenesis and angiogenesis are unaffected by grade,
the different prognoses are not likely to be due to differ-
ences in lymphatic or blood vessel synthesis. The only two
histopathological types analysed in this study were inva-
sive ductal adenocarcinoma and invasive lobular adeno-
carcinoma. Although other types were seen, the numbers
of each were too small for statistical analysis. This study
indicated that the rate of lymphangiogenesis and angio-
genesis was similar in both of the main tumour types.
Conclusion
In summary, the findings from this study show that lym-
phangiogenesis, measured by specific lymphatic marker
expression, is higher in breast cancers than in normal
breast tissue. Secondly, breast cancers which have metas-
tasised to the regional lymphatics show higher expression
compared to those which have not, although the individ-
ual differences for all five markers were not statistically
significant The VEGF-C:VEGF-D ratio ratio however was
significantly higher in the node node +ve group which
concurs with previous studies [21,22] which link this rela-
tionship to poor prognosis. Finally, expression of the lym-
phangiogenic factors, VEGF-C and VEGF-D were also
higher in cancers which had metastasised than those
which had not, but again differences were not significant.
The potential therapeutic possibilities of targeting lym-
phangiogenic factors in breast cancer using VEGFR-3
antagonists [45,46], COX-2 antagonists [47], IL-7 antago-
nists [48] and others have been the subject of recent
intense investigation [49]. This may be of particular
importance in young premenopausal patients with poorly
differentiated [50] or inflammatory cancers [51,52].
Although our findings do not statistically support the
hypothesis that lymphangiogenesis is correlated with
lymphatic metastasis we feel that larger studies are needed
to assess this further.
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